News

Number of news items returned: 161 to 180 records of 411

Benojo - Latest News - June 2016

15 June 2016

(11664 views)

"As the client base grows and tech releases are almost daily Benojo is establishing itself as a philanthropic platform of ...

Ocular Robotics Releases 'RobotEye Thermal' Product Range

15 June 2016

(11538 views)

"Ocular Robotics is excited to announce the release of the RELW60 Thermal product range. This extension of the RobotEye product ...

Ocular Robotics: Successful Demonstration to US Defence

15 June 2016

(11343 views)

"The company is pleased to announce a recent successful demonstration of one of OCR’s products integrated onto a target platform ...

REHS25 Hyperspectral Sees Beyond Human Vision

15 June 2016

(11093 views)

"Of particular note in the demonstrations shown recently at the Image Sensing Show in Yokohama by OCR’s Japanese distributor ViewPLUS ...

Simultaneous Impressive Displays by OCR's Japanese Distributor ViewPLUS Inc.

15 June 2016

(10987 views)

"Ocular Robotics’ distributor in Japan, ViewPLUS Inc. had an impressive display of the company’s products at the Image Sensing Show ...

Paradigm & IODM - Offers Extended

03 June 2016

(12192 views)

"Paradigm Metals Limited is pleased to announce that it has received conditional approval from ASX to the re-quotation of its ...

Introducing Freedom Suites, Benojo, EOI's and News - Funding Strategies Connect May June 2016

30 May 2016

(11740 views)

Introducing Freedom Suites, Benojo, EOI's and News - Funding Strategies Connect May/June 2016 Dear Readers, I had a very interesting time visiting ...

ATIC reports Stellar Investment Portfolio Performance

26 May 2016

(11875 views)

 ATIC reports Stellar Investment Portfolio Performance Australian Trading and Investment Corporation Ltd reports: " Outstanding investment portfolio performance Expanded product/service offer ATIC is holding ...

Benojo - Latest news - May 2016

24 May 2016

(12643 views)

"As Benojo begins to ramp up in the Australian domestic market it attracts a globally recognised CEO, US interest, acquires ...

BlueMount Capital WA Office bolsters portfolio offering in the Food & Beverages Sector

23 May 2016

(12040 views)

BlueMount Capital WA Office bolsters portfolio offering in the Food & Beverages Sector "The Western Australian Office of BlueMount Capital is ...

Opmantek recognised as one of America's most innovative companies in the 2016 American Business Awards

23 May 2016

(11900 views)

OPMANTEK RECOGNISED AS ONE OF AMERICA’S MOST INNOVATIVE COMPANIES IN THE 2016 AMERICAN BUSINESS AWARDSSM " Opmantek has been named as one of America’s most ...

BR Sustainable Investments Australia Recommends Trac Offer

20 May 2016

(12222 views)

" Please read the prospectus documents. ASX code TRC, bookbuild code TRCXBB. We recommend the offer. The levels of CO2 in the atmosphere ...

Paradigm & IODM - Extension of Offer

05 May 2016

(11887 views)

"Paradigm Metals Limited (ASX: PDM) wishes to announce that the Offers under the Prospectus dated 1 April 2016 have been ...

IODM signs strategic alliance agreement with National Credit Insurance

05 May 2016

(12370 views)

"Melbourne, Australia –- May 5, 2016: Paradigm Metals Limited (“Paradigm” or “the Company”) is pleased to announce that IODM has ...

Introductions to Solar, Balustrades, Automated AR Cycle plus news - Funding Strategies Connect April May 2016

29 April 2016

(11678 views)

  Introductions to Solar, Balustrades, Automated AR Cycle plus news - Funding Strategies Connect April/May 2016 Dear Readers, As I am heading off ...

Ocular Robotics: The Company Appoints Turkish Distribution Partner LEO Engineering, and Impressive Display of Ocular Robotics’ Products at Connect Expo 2016

26 April 2016

(12202 views)

"Ocular Robotics Appoints Turkish Distribution Partner LEO Engineering Ocular Robotics is pleased to announce the appointment of Turkish automation technology reseller ...

Opmantek in record period of growth

26 April 2016

(12207 views)

"The Opmantek management team was pleased to report excellent Q1 closing figures during a shareholder update web conference last Thursday. “The ...

IODM Market Update

26 April 2016

(11785 views)

" Paradigm Metals Limited (“Paradigm” or “the Company”) is pleased to provide an IODM Market Summary as provided by the management of IODM. Focus ...

Integrity Compliance Systems' CEO invited to speak at major food safety conferences

22 April 2016

(12269 views)

" ICS provide the only training course in Australia for Vulnerability Assessment and Critical Control Points (VACCP) plan, which is now ...

ATIC: New Revenue Streams

22 April 2016

(12426 views)

"Funds Management services to start in June 2016 Until now ATIC’s core product has been equity research, and resulting buy/sell share ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625